BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 24,000 shares, a decrease of 21.6% from the November 15th total of 30,600 shares. Based on an average daily trading volume, of 91,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BWAY shares. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities raised their target price on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research note on Thursday, October 3rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after purchasing an additional 1,695 shares during the period. Perritt Capital Management Inc bought a new stake in shares of BrainsWay during the 2nd quarter valued at $121,000. Good Life Advisors LLC grew its position in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after buying an additional 22,080 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of BrainsWay by 48.1% in the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after acquiring an additional 84,371 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Stock Performance

BWAY stock traded down $0.31 on Friday, reaching $9.42. The company’s stock had a trading volume of 44,454 shares, compared to its average volume of 93,510. The firm has a market cap of $157.11 million, a PE ratio of 94.20 and a beta of 1.23. The business has a fifty day simple moving average of $9.87 and a two-hundred day simple moving average of $8.12. BrainsWay has a 12-month low of $4.61 and a 12-month high of $10.98.

BrainsWay (NASDAQ:BWAY) last announced its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The firm had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. During the same quarter in the previous year, the firm posted ($0.01) EPS. As a group, research analysts anticipate that BrainsWay will post 0.06 earnings per share for the current fiscal year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.